fda-and-biotech News
Nurix Stock Soars on Promising Blood Cancer Drug Data
Shares surge over 12% after its BTK degrader, bexobrutideg, shows high response rates in heavily pre-treated leukemia and lymphoma patients.
Ocular Therapeutix Soars 23% on Accelerated FDA Path for Eye Drug
Company plans faster submission for its wet AMD treatment, AXPAXLI, after positive FDA guidance, challenging market leaders like Regeneron's Eylea.
Autolus Surges on 95% Remission Rate for Leukemia Therapy Obe-cel
Shares in the biotech firm climb as new data shows its CAR-T therapy has a superior safety and efficacy profile in pediatric patients.
Vertex Previews Casgevy Expansion to Young Patients With New Data
Data from the ASH conference shows the gene therapy's efficacy in children as young as five, reinforcing its potential beyond its initial approval.
Harmony Biosciences Jumps on Positive Epilepsy Drug Data
Shares rise after company's EPX-100 drug candidate shows a 50% reduction in seizure frequency for patients with severe, treatment-resistant Dravet syndrome.
Geron Shares Rise on Favorable Rytelo Drug Data at ASH Conference
New analysis suggests a key side effect of the MDS treatment is linked to its clinical effectiveness, bolstering the drug's profile among clinicians.
Syndax Hits 52-Week High on Strong Leukemia Drug Data
Shares surge as new real-world and clinical data from the ASH conference reinforce the efficacy of its recently approved drug, revumenib.
HUTCHMED Gains Expanded China Drug Coverage For Cancer Trio
Inclusion in the national reimbursement list is a key catalyst for market access and revenue growth, setting the stage for Monday's trading session.